Alps Advisors Inc Protagonist Therapeutics, Inc Transaction History

Alps Advisors Inc

$15.7 Billion
Q4 2024

A detailed history of Alps Advisors Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Alps Advisors Inc holds 55,941 shares of PTGX stock, worth $2.16 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

55,941

Previous 52,032 7.51%

Holding current value

$2.16 Million

Previous $2.34 Million 7.66%

% of portfolio

0.01%

Previous 0.02%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$38.51 - $48.43 $150,535 - $189,312	3,909 Added 7.51%	55,941 $2.16 Million
Q3 2024 Nov 12, 2024	BUY	$33.72 - $47.33 $211,087 - $296,285	6,260 Added 13.68%	52,032 $2.34 Million
Q2 2024 Aug 13, 2024	BUY	$24.66 - $34.8 $115,236 - $162,620	4,673 Added 11.37%	45,772 $1.59 Million
Q1 2024 May 14, 2024	BUY	$21.79 - $32.15 $22,378 - $33,018	1,027 Added 2.56%	41,099 $1.19 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $33,396 - $55,716	-2,377 Reduced 5.6%	40,072 $918,000
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $6,138 - $8,706	368 Added 0.87%	42,449 $708,000
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $174,181 - $283,793	9,666 Added 29.82%	42,081 $1.16 Million
Q1 2023 May 10, 2023	SELL	$10.78 - $25.38 $10,068 - $23,704	-934 Reduced 2.8%	32,415 $745,000
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $48,046 - $72,917	6,528 Added 24.34%	33,349 $363,000
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $16,097 - $23,982	-2,048 Reduced 7.09%	26,821 $226,000
Q2 2022 Aug 11, 2022	SELL	$7.06 - $25.52 $147,490 - $533,138	-20,891 Reduced 41.98%	28,869 $228,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $127,716 - $197,429	-5,472 Reduced 9.91%	49,760 $1.18 Million
Q4 2021 Feb 09, 2022	BUY	$17.63 - $37.1 $573,644 - $1.21 Million	32,538 Added 143.38%	55,232 $1.89 Million
Q2 2018 Jul 25, 2018	SELL	$5.99 - $9.1 $28,596 - $43,443	-4,774 Reduced 17.38%	22,694 $472,000
Q1 2018 May 01, 2018	BUY	$8.46 - $23.08 $40,388 - $110,183	4,774 Added 21.04%	27,468 $236,000
Q4 2017 Feb 05, 2018	BUY	$14.47 - $20.8 $328,382 - $472,035	22,694	22,694 $472,000

Others Institutions Holding PTGX

# of Institutions

253

Shares Held

58.9M

Call Options Held

226K

Put Options Held

218K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.9B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Protagonist Therapeutics, Inc Transaction History